SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bob Swift who wrote (2859)5/19/1999 5:16:00 PM
From: Biomaven  Read Replies (1) of 10280
 
Bob,

During the Q&A session I asked a question about the patent issues surrounding Meridia (sibutramine), which expires in 2001 (or maybe 2002, I forget) but Knoll has a five year Waxman-Hatch extension coming to them. The response was that their view was that the extension did not apply to their ICE, because it was a different drug. I asked what Knoll thought about that, and the response was that Knoll was being very reasonable (or maybe that they were reasonable people). My inference (and it's only an inference) is that they have had some discussions with Knoll about it. If so, and they ended up partnering, one guess would be that Knoll would take the obesity indication and they would take the rest.

Meridia is a tough sell in its present formulation because one of its possible side effects is a significant rise in blood pressure, the last thing most obese people need. I think the dose is limited by the side effects, and so its effectiveness is often marginal.

I believe their ICE (which is an isomer of a metabolite) does not have this side effect. They are talking about exploring its effect on a wide variety of conditions (like refractory depression) but interestingly didn't mention obesity. Meridia was actually originally developed as an antidepressant, by the way.

They also said they intend to devote a good chunk of their R&D budget to the sibutramine ICE. It definitely seemed to be the candidate in their pipeline that they were most excited about. (This isn't really new - I posted something about this a few months back).

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News